Less than 10% of individuals that would benefit from GLP-1 drugs such as Wegovy have access to them, states the WHO as it releases its initial recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Per estimates, more than two billion could be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that excess weight is a long-term condition that can be managed with holistic and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major barriers to broad availability to the treatments that can aid individuals in losing substantial body mass, explains the body.
Skinny Jab Supply Crisis
Even in the current best projected scenario, the manufacturing of these medications would only suffice for about 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation urges governments and firms to expand availability, via approaches such as voluntary licensing.
Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Injections Function
GLP-1 drugs mimick a body's own hormone to slow digestion, reduce hunger and boost satiety so people consume fewer calories.
Individuals typically see weight reduction in the initial weeks of beginning the weekly injections.
Studies suggests people may put most of the weight back on after a year of halting the treatment, as their typical hunger resume.
Being carrying excess weight raises your likelihood for experiencing medical conditions, like diabetes, heart disease, brain attack, and some cancers.
Excess weight impacts people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
